Avon Settlement With Feds Over Bribery Charges Could Reach $132 Mil.
This article was originally published in The Rose Sheet
Executive Summary
Firm is optimistic that an end to negotiations with federal agencies regarding alleged misconduct in China could be on the horizon. However, the firm’s sales continue to suffer as the firm labors to right its business.
You may also be interested in...
Avon Faces Potential High Penalties Under SEC Deal; Q3 Sales Down 7%
Avon says the impact of a settlement with the U.S. Securities and Exchange Commission and Department of Justice to resolve investigations into its foreign business practices in recent years could be significantly greater than planned for. Meanwhile, the firm works to rebuild its direct-sales platforms in North America, where declines in field representatives have created a drag on revenue.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.